openPR Logo
Press release

May renal cell carcinoma be cured by EMIT?

03-14-2016 04:02 PM CET | Health & Medicine

Press release from: PBirkel

A 50 year-old male patient asked for help: A left-sided renal mass had been detected in an abdominal CT-scan performed due to a preceding gross hematuria. Abdominal CT-scan: Inhomogeneous tumor with a diameter of approximately 9.5 cm in the left kidney. Additionally, several enlarged aortic lymph nodes (about 8 mm in size) as well as a tumor in the left adrenal with a diameter of 10 mm.

Pathological evaluation
Macroscopy: Left kidney, extirpated in toto, with a solid, partially hemorrhagic tumor measuring ca. 8 cm, which invades into the pelvic space as well as into the renal capsule. Norenal vein thrombosis could be detected. Microscopy revealed a clear cell renal carcinoma with obvious invasion into the adjacent vessels and renal capsule. Some mitoses were to be observed.

Treatment with EMIT
After surgical removal of the left kidney we treated the patient with EMIT in various sessions from mid November 2014 till February 2015, according to your instructions. No other medical interventions were carried out. During the procedure neither any side effects were observed nor did the patient complain about any discomfort. Until now, no signs of recurrence have appeared, and the patient leads a normal life again.

In order to evaluate whether or not any tumor reactive cells still exist in the patient's peripheral blood after one year, we recently re-tested his leukocytes against his cryopreserved tumor cells. As documented below, there were a lot of leukocytes that promptly recognized the tumor cells. Therefore we dare to deduce that our patient's cancer has effectively been treated with EMIT procedure.

Primary findings in brief (original copies incl.):
http://soezmed.com/wp-content/uploads/2016/03/EMIT-Turkey.pdf

article by:
Dr. Ömer Ozan Öz
Istanbul -Turkey

Dr. med. Sadık Öz • Feuerweg 21 • 90443 Nürnberg • +49 911 92919620
contact@soezmed.com

Dr. Sadik Öz’s scientific publications prove that the ideas he propagate are based on solid scientific background. For example, his doctoral thesis provided the some basic knowladge for a substance (G-CSF) which is nowadays used for preventing Leukocytopenia after chemotherapy, and for gaining peripheral stem cells for bone marrow transplantation. Moreover, he established several cell lines (e. g. GM/SO, LW/SO) for In-Vitro-Examination of Leucocytes and bone marrow cells as well as various corresponding biological tests.
He was a very active and successful scientist. However, after refusing to cede a not yet published, promising result to another colleague, his academic career had been terminated. Yet, thanks to the support of some mentors and institutions, he continued to follow his ideas in other places, even after starting to work in his own practice as a doctor for internal medicine. Apart from EMIT, he developed other very successful immunological modes of treatment for bronchial asthma and acuminate condyloma etc, over the course of many years.

Dr. med Sadik Öz (SOEZMED):

STUDY (1979 − 1985)
Human Medicine at the University of Regensburg ( Physikum ) or University Erlangen-Nuremberg

MEDICAL EDUCATION (1988 − 1995)
in the Med . Klinik III Uni – Erlangen Med . Clinic IV , Klinikum Nürnberg and Med . Clinic V , Nuremberg Hospital

CANCER RESEARCH (SINCE 1981)

September 1981 – September 1985 − Doctoral thesis
September 1985 – August 1986 − Assistant Professor at the Department of Immunology and Rheumatology,
Med . Klinik III Uni – Erlangen
September 1986 – June 1987 − Researcher at the Sloan Kettering Cancer Center, New York, USA
July 1987 – January 1988 − MHH Hannover Pediatric Oncology
February 1988 – December 1991 − Med. Klinik III Uni-Erlangen Haematological malignancies
July 1991 – August 1995 − Med. Klinik V, Klinikum Nürnberg Haematological malignancies
September 1995 to date − Independent researcher

DOCTOR’S SURGERY SINCE 1995

Dr. med. Sadık Öz • Feuerweg 21 • 90443 Nürnberg • +49 911 92919620
contact@soezmed.com

Peter Birkel
Bogenstr. 5
91233 Neunkirchen
Tel. 09123/14957
mail: birkel2334@googlemail.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release May renal cell carcinoma be cured by EMIT? here

News-ID: 325893 • Views: 976

More Releases from PBirkel

03-17-2016 | Health & Medicine
PBirkel
The new concept: EMIT - CANCER IS CURABLE
The new concept: EMIT - CANCER IS CURABLE In the course of approximately 30 years in cancer research (see curriculum vitae) I have been trying to work out a new strategy to overcome the problems mentioned above. Based on my observations I assume that the mode of therapy should comprise not only the destruction of the tumor cell, but should focus on its “conversion”, “re-education” into normal functioning body cells. I
03-17-2016 | Health & Medicine
PBirkel
Extracorporal Modified Immune Therapy (EMIT)
A tumor patient usually does not die from a benign tumor, but from a malignant tumor that maintains an uninhibited proliferation, which in turn interferes fatally with the vital functions of other organs. Apart from surgical procedures at an early stage, conventional cancer therapy is based on the philosophy that cancer cells should be destroyed with various destructive methods such as chemotherapy, radiation therapy, TKI, monoclonal antibodies, etc. All immunological research
03-15-2016 | Health & Medicine
PBirkel
An alternative cancer treatment: Extracorporal Modified Immune Therapy (EMIT)
EMIT is based on the special cultivation of somatic tumor cells and leucocytes of patients, it would be subject to such regulation, too. Due to such financial and administrative obstacles it is almost impossible to offer this promising treatment for public use.  If a physician acts against these regulations, this would be regarded as an indictable offence as mentioned above. Moreover, other problems emerge: Those who do not belong to academic

All 4 Releases